BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834
November 01, 2017 at 08:35 AM EDT
* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)
